Objective: To determine pregnancy outcome, including the rate of repeat molar pregnancy, following histologically confirmed complete or partial hydatidiform mole.
Design: Retrospective review of a large supraregional database of registrations for gestational trophoblastic disease.
Setting: Supraregional Trophoblastic Disease Unit, London.
Sample: Women with pregnancies affected by complete or partial hydatidiform mole registered between 1992 and 1998.
Methods: All patients with a diagnosis of histologically confirmed complete or partial hydatidiform mole were identified and data on subsequent pregnancies compared between groups using comparison of proportion test.
Main Outcome Measures: Pregnancy outcome by partial or complete mole subtype, with particular regard to risk of subsequent molar pregnancy.
Results: Of 2578 complete moles, the subsequent pregnancy was affected by hydatidiform mole in 27 (1.9%) cases, including 22 (81%) complete moles and 5 (19%) partial moles. Of 2627 partial moles, the subsequent pregnancy was also molar in 25 (1.7%) cases, including 17 (68%) partial moles and 8 (32%) complete moles. Overall recurrence risk for molar pregnancy was 1.8% (1 in 55), or a 20-fold increase compared with the background risk. Of 27 cases with repeat complete moles, three had further complete moles, suggesting the recurrence risk following two previous complete moles is approximately 10%. There were no other significant differences in pregnancy outcome between cases with previous complete or partial hydatidiform mole and that expected in an unselected obstetric population.
Conclusions: Women having a pregnancy affected by a histologically confirmed complete or partial hydatidiform mole may be counselled that the risk of repeat mole in a subsequent pregnancy is about 1 in 60 and if this were to occur, the majority of cases will be of the same type of mole as the preceding pregnancy. However, >98% of women who become pregnant following a molar conception will not have a further hydatidiform mole and these pregnancies are at no increased risk of other obstetric complications.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Serum hCG levels in the prediction of molar pregnancy below 11 weeks of gestational age.
Rev Assoc Med Bras (1992)
December 2024
Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Obstetrics - São Paulo (SP), Brazil.
Objective: The aim of this study was to evaluate the serum hCG level in the differential diagnosis between non-molar miscarriage and complete hydatidiform mole in<11 weeks gestation.
Methods: This was a retrospective collaborative cohort study. This study included women with gestational age<11 weeks, with ultrasound evidence of failed pregnancy and available serum hCG pre-uterine evacuation, divided into two groups: the non-molar miscarriage group and the complete hydatidiform mole group.
Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy.
Aust N Z J Obstet Gynaecol
December 2024
Queensland Trophoblast Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Objectives: To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first-line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).
Methods: Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.
Hysteroscopy improves surgical outcomes of hydatidiform moles while reducing postoperative residuals.
Am J Transl Res
November 2024
Department of Obstetrics and Gynecology, Shanxi Children's Hospital Shanxi Maternal and Child Health Hospital Taiyuan 030001, Shanxi, China.
Objective: To evaluate the clinical efficacy of hysteroscopy in the treatment of molar pregnancy and postoperative residual tissue.
Methods: This retrospective study involved 68 patients who underwent treatment for molar pregnancy in Shanxi Children's Hospital Shanxi Maternal and Child Health Hospital from April 2020 to May 2022. Based on intervention methods, patients were divided into a conventional group (n=33) and a hysteroscopy group (n=35).
Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
Gynecol Oncol
December 2024
Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN).
Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical characteristics, World Health Organization risk score (low-risk 0-6, high-risk ≥7), and treatments/outcomes were evaluated using summary statistics, stratified by initial treatment at a referral center versus locally.
Vaginal metastasis in gestational trophoblastic neoplasia: Experience from Sheffield trophoblastic disease Centre and recommendations for management.
Eur J Obstet Gynecol Reprod Biol
November 2024
Sheffield Trophoblastic Disease Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Introduction: Gestational trophoblastic neoplasia (GTN) is rare in the UK, with an estimated incidence of one in 50,000 live births. Cases of vaginal metastasis are even rarer, with only eight case series reporting 187 cases over the past 40 years. Management recommendations in the literature are scarce despite the potential risk of massive, potentially life-threatening vaginal haemorrhage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!